ROSEN, GLOBAL INVESTOR COUNSEL, Encourages ESSA Pharma Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EPIX
ESSA Pharma Reports Q1 Loss, Explores Strategic Options
ESSA Pharma GAAP EPS of -$0.19 Misses by $0.01
Essa Pharma Reports Q4 EPS (19c) Vs. (14c) Last Year
ESSA Pharma | 8-K: ESSA Pharma Reports Financial Results for Fiscal First Quarter Ended December 31, 2024
Express News | ESSA Pharma Inc - Strategic Options Include Merger, Take-Over, Asset Sale
Express News | ESSA Pharma Inc - Terminates Masofaniten Clinical Trials, Exploring Strategic Options
Essa Pharma Had Available Cash Reserves and Short-Term Investments of $120.6M at Dec 31 >EPIX
ESSA Pharma | 10-Q: Q1 2025 Earnings Report
Express News | ESSA Pharma Q1 Operating Expenses USD -9.685 Million
Essa Pharma 1Q Loss/Shr 19c >EPIX
Press Release: ESSA Pharma Reports Financial Results for Fiscal First Quarter Ended December 31, 2024
When Will ESSA Pharma Inc. (NASDAQ:EPIX) Turn A Profit?
ESSA Pharma's Cash Management: A Potential Risk to Shareholder Value and Market Stability
ESSA Pharma Inc. Reports Strategic Shift Amid Losses
ESSA Pharma: Fiscal Q4 Earnings Snapshot
ESSA Pharma Q4 2024 GAAP EPS $(0.14) Beats $(0.21) Estimate, Cash Balance Of $103.71M
ESSA Pharma | 8-K: ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024
Express News | ESSA Pharma Inc: Strategic Review Expected to Involve Headcount and Other Cost Reductions
Express News | ESSA Pharma Inc: Initiated Comprehensive Process to Explore and Review a Range of Strategic Options